Cloud Hosting

Text size

Two companies, Achilles Therapeutics and Coursera, made their entrance as public companies Wednesday.Shares of Coursera rose as much as 23%, while Achilles dropped below its $18 offer price.

Courseras (ticker: COUR) stock opened at $39 and recently traded at $38, up about 15% from its $33 offer price.

Late Tuesday, the Mountain View, California company sold 15.73 million shares at the top of its $30 to $33 price range, collecting $519 million.

Founded in 2012, Coursera provides an online learning platform, offering about 5,100 courses and specializations to individuals. Students can take classes such as Japanese for Beginners, Predictive Analytics & Data Mining, or Covid-19 Contact Tracing, and they can earn a degree or an online certificate. The company said its platform has attracted more than 77 million learners. Classes are meant to be affordable, with a bachelors or masters degree ranging from $9,000 to $45,000, the prospectus said.

The company, however, isnt profitable, reporting $66.8 million in losses on $293.5 million in revenue for the year ended Dec. 31.

Achilles (ACHL) also made its debut. The biotech raised $175.5 million after selling 9.75 million American depositary shares at $18, the middle of its $17 to $19 price range. Each ADS represents one ordinary share.

The stock opened at $18, but recently changed hands at $17.10, down 5% from its initial public offering price. This makes Achilles a broken deal.

Achilles is developing T-cell therapies to treat cancer. It is conducting two open-label Phase I/IIa trials to evaluate its product candidate, ATL001, for use in advanced non-small cell lung cancer and metastatic or recurrent melanoma.

Achilles isnt profitable and hasnt generated revenue. Losses widened to $33.2 million for the year ended Dec. 31 from about $14 million in 2019, a prospectus said.

Write to editors@barrons.com

Follow this link:

Achilles Therapeutics and Coursera Stock Start Trading. What You Need to Know. - Barron's